Can BCR inhibitors be used to treat all CLL patients or only a subset?
TGR-1202, a next generation PI3K-delta inhibitor in CLL and B-cell lymphomas
TGR-1202, novel PI3K delta inhibitor, for hematological malignancies
The next steps for TGR-1202 and targeting the gene c-Myc
TGR-1202- a new generation PI3K delta inhibitor for CLL